Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (August 2009)

22 slides from Zydus Lifesciences's investor presentation, August 2009

  1. Slide 1: Cadila Healthcare Ltd. Investor Presentation

    Cadila Healthcare Ltd. Investor Presentation August 2009 1

  2. Slide 2: A Snapshot

    A Snapshot  One of the oldest and the 5th largest in the Indian formulations market worth over Rs. 350 bn (Source : ORG IMS MAT Jun-09)  Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa, Middle East and CIS regions  International sales in generic markets contribute to over 33%

  3. Slide 3: Priorities achieved: 2008-09

    Priorities achieved : 2008-09 Strategic forays in key  Acquired Laboratorios Combix to enter Spain and acquired majority stake in Simayla markets Pharmaceuticals, South Africa Continued research focus  Invested over 6% of revenue on research. Filed IND ZYT1 with DCGI and USFDA Strengthening the 

  4. Slide 4: Financial highlights

    Financial highlights # Net Profit and EPS excludes Exceptional Items 4

  5. Slide 5: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Goa Sikkim Baddi API, Dabhasa Finished Dosage Form, API, Ankleshwar (USFDA approved) Moraiya (USFDA Approved) (USFDA Approved) Pantoprazole Intermediates Cytotoxic Injectables Fine Chemic

  6. Slide 6: Core business areas and Revenue break-up (FY 08-09)

    Core business areas and Revenue break-up (FY 08-09) Revenue break-up by segment Revenue break-up by region 6

  7. Slide 7: 5th largest in Indian Pharma market

    5th largest in Indian Pharma market with over Rs 12 bn sales  Leading positions in key segments – CVS, Therapeutic Area-wise Sales Break-up of GI, Female Healthcare and Respiratory Branded Formulations (FY 08-09) (participated market segments)  15 brands feature amongst the top 300 Dermatology Neu

  8. Slide 8: International formulations: two-fold focus

    International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets which constitute 22 % of which contribute to 11 % of global sales global sales  US - Zydus Pharmaceuticals USA Inc.  Brazil –  Europe • Branded - Quimica e Pharmaceutica Nikkho Do

  9. Slide 9: One of the fastest growing generic companies in US

    One of the fastest growing generic companies in US Gross Sales  Started operations in 2005 and adopted a “Customer Centric Model”  25 products launched. 8 -10 products to be added every year  Products enjoy 5 - 25% market share  Focusing on delivery based, difficult to make products, the next gr

  10. Slide 10: Over 2.5% market share in French market; launches in Spain

    Over 2.5 % market share in participated French market; 24 product launches in Spain Strong presence in Euro 2.3 bn French market Gross Sales  Rated one of the fastest growing companies in France by IMS  Launched >150 presentations (~75 molecules) in France  Continuous focus on enrichment of custo

  11. Slide 11: Strategies for world's 2nd largest market: Japan

    Strategies for world’s 2nd largest market valued at $3bn : Japan  Market valued at $ 3 bn, growing at ~12%, with very low generic penetration of ~5% in value terms, 17% in volume terms (Source : IGPA)  Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufacturing f

  12. Slide 12: Achievements in the $12bn Brazilian pharma market

    Achievements in the $ 12bn Brazilian pharma market growing at 15-18% p.a. Gross Sales  Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06  Filed 47 dossiers so far for generic and branded products from India, of which 19 have been approved. Launched 16 generi

  13. Slide 13: Exports to emerging markets grew by >30%

    Exports to emerging markets grew by >30% in last 4 years Gross Sales  Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa, Middle East and CIS regions  Focusing on rapidly growing markets of Russia, South Africa, Taiwan and Philippines  No.1 Indian company in Ugand

  14. Slide 14: Zydus Wellness – A market leader with iconic and niche consumer brands

    Zydus Wellness – A market leader with iconic and niche consumer brands Restructured consumer business with de-merger of consumer business from Cadila Healthcare into Carnation in FY 08-09. Company now renamed as Zydus Wellness Ltd. 14

  15. Slide 15: A pioneer in the low calorie sweetener segment and skincare

    A pioneer in the low calorie sweetener segment and a trendsetter in skincare products  Sugar Free – India’s largest selling sugar substitute with market share of over 82% (Source : AC Nielsen).  Growing at CAGR of 25% for last 3 years, the brand recorded sales of Rs. 778 Mio. in FY 08-09  Everyut

  16. Slide 16: Unlocking value through win-win alliances

    Unlocking value through win-win alliances  Zydus Nycomed JV – most successful contract manufacturing JV in India  State-of-the-art API mfg. plant for Pantoprazole intermediates  Expanded scope - more APIs to be sourced by Nycomed from this JV  Zydus Hospira - JV for oncology injectables (Generic

  17. Slide 17: Ongoing Investment in Newer Portfolios Worth over $180 bn

    Ongoing Investment in Newer Portfolios Worth over $ 180 bn Zydus New Portfolio Mid term Zydus New Portfolio • Biogenerics: 40 bn Near term • Transdermal: 10 bn • Vaccine: 22 bn Oral • Pulmonary: 20 bn • Topical: 16 bn • Transdermal: 10 bn • One of the leading player • Injectables: 17 bn in regulator

  18. Slide 18: A scientific talent pool of 850 and investing over 6% on research

    A scientific talent pool of 850 and investing over 6% of the turnover on research Talent Pool of ~850 Scientists Zydus Research Centre (ZRC)  Located in Ahmedabad Generics/ Developmental  Focus on NME Research, 335 scientists Biologicals & NDDS Pharmaceutical Technology Centre NME & Drug (PTC) Dis

  19. Slide 19: Dedicated facility for NME research: Zydus Research Centre

    Dedicated facility for NME research : Zydus Research Centre  Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation  Facility for target identification to pre-clinical research / early clinical development  2nd company in India to be accredited by AAALAC (Association for Assessment and Acc

  20. Slide 20: Highlights: Q1 FY 09-10 Results

    Highlights : Q1 FY 09-10 Results Rs. Mio. Consolidated Growth Q1 09-10 Q1 08-09 y-y% Domestic Sales 4,758 4,213 12.9% Exports Sales 4,138 2,765 49.7% Total Gross Sales 8,896 6,978 27.5% Total Operating Income 9,035 7,140 26.5% EBIDT 2,036 1,617 25.9% EBIDT % to Total Income 22.6% 22.6% Net Profit #

  21. Slide 21: Our Vision

    Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020. 21

  22. Slide 22: Safe Harbour Statement

    Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims a

Cadila Healthcare — Investor Presentation (August 2009) on 6ix